Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-07-31
1998-02-03
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514149, 5142382, 514255, 514314, 514492, 514494, 514499, 514558, 514563, 514564, 514601, 514610, 514611, 514647, 514649, A61K 3140, A61K 31655, A61K 31535, A61K 31495, A61K 3147, A61K 3128, A61K 31315, A61K 3130, A61K 3120, A61K 31195, A61K 3118, A61K 3104, A61K 3113, A61K 31135
Patent
active
057145113
ABSTRACT:
A method for the treatment of mammalian tissue injured or at risk of injury during sepsis or shock including the administration to a mammal a diazeniumdiolate which releases a therapeutically effective amount of nitric oxide sufficient to protect the tissue from sepsis- or shock-induced injury.
REFERENCES:
patent: 3153094 (1964-10-01), Reilly
patent: 3826832 (1974-07-01), Anderson et al.
patent: 4265714 (1981-05-01), Nolan et al.
patent: 4482533 (1984-11-01), Keith
patent: 4638079 (1987-01-01), Inskip et al.
patent: 4708854 (1987-11-01), Grinstead
patent: 4921683 (1990-05-01), Bedell
patent: 4952289 (1990-08-01), Ciccone et al.
patent: 4954526 (1990-09-01), Keefer
patent: 4985471 (1991-01-01), Ohta et al.
patent: 5039705 (1991-08-01), Keefer et al.
patent: 5087631 (1992-02-01), Shaffer et al.
patent: 5087671 (1992-02-01), Loeppky et al.
patent: 5094815 (1992-03-01), Conboy et al.
patent: 5155137 (1992-10-01), Keefer et al.
patent: 5208233 (1993-05-01), Keefer et al.
patent: 5212204 (1993-05-01), Keefer et al.
patent: 5234956 (1993-08-01), Lipton
patent: 5250550 (1993-10-01), Keefer et al.
patent: 5366997 (1994-11-01), Keefer et al.
patent: 5389675 (1995-02-01), Christodoulou et al.
patent: 5405919 (1995-04-01), Keefer et al.
Adams et al., "Electron-Affinic Sensitization," Radiation Research, 67, 9-20 (1976).
Alston et al., "Generation of Nitric Oxide by Enzymatic Oxidation of N-Hydroxy-N-Nitrosamines," J. Biol. Chem., 260 (7), 4069-4074 (1985).
Ames et al., "Uric Acid Provides An Antioxidant Defense in Humans Against Oxidant-And Radical-Caused Aging and Cancer: A Hypothesis," Proc. Natl. Acad. Sci. USA, 78, 6858-6862 (1981).
Andrade et al., "Inhibitors of Nitric Oxide Synthase Selectively Reduce Flow in Tumour-Associated Neovasculature," Br. J. Pharmacol., 107, 1092-1095 (1992).
Andrews et al., "Protection Against Gastric Reperfusion Injury by Nitric Oxide: Role of Polymorhophonuclear Leukocytes," Gastroenterology, 104, A33 (1993).
Aoki et al., "Beneficial Effects of Two Forms of NO Administration in Feline Splanchnic Artery Occlusion Shock," Am. J. Physiol., 258, G275-G281 (1990).
Artysbasheva et al., "Synthesis of 1-Alkoxy-3,3-Dialkyltriazene 2-Oxides from Alkoxyamines and Nitrosoamines," translated from Zhurnal Organicheskoi Khlmii (J. Organic Chemistry-U.S.S.R.), 28, (6) 1168-1173 (1987).
Beckman et al., "Apparent Hydroxyl Radical Production by Peroxynitrite: Implications for Endothelial Injury From Nitric Oxide and Superoxide," Proc. Natl. Acad. Sci. USA, 87, 1620-1624 (1990).
Beckman, "The Double-Edged Role of Nitric Oxide in Brain Function and Superoxide-Mediated Injury," J. Developmental Physiol., 15, 53-59 (1991).
Beckman, "Ischaemic Injury Mediator," Nature, 345, 27-28 (1990).
Bedford et al., "Threshold Hypoxia: Its Effect on the Survival of Mammalian Cells Irradiated at High and Low Dose-Rates," Br. J. Radiol., 39, 896-900 (1966).
Bohn et al., "Oxygen and Oxidation Promote the Release of Nitric Oxide from Sydnonimines," J. Cardiovasc. Pharmacol., 14, S6-S12 (1989).
Bonakdar et al., "Continuous-Flow Performance of Carbon Electrodes Modified With Immobilized Fe(II)/Fe(III) Centers," Calanta, 36, 219-225 (1989).
Coleman et al., "Phase I Trial of the Hypoxic Cell Radiosensitizer SR-2508: The Results of the Five to Six Week Drug Schedule," Int. J. Radiat. Oncol. Biol. Phys., 12, 1105-1108 (1986).
Dawson et al., "Nitric Oxide Synthase and Neuronal NADPH Diaphorase Are Identical in Brain and Peripheral Tissues," Proc. Natl. Acad. Sci. USA, 88, 7797-7801 (1991).
DeFeudis, "Endothelium-Dependent Vasorelaxation--A New Basis for Developing Cardiovascular Drugs," Drugs of Today, 24(2), 103-115 (1988).
DeGraff et al., "Evaluation of Nitroimidazole Hypoxic Cell Radiosensitizers in a Human Tumor Cell Line High in Intracellular Glutathione," I. J. Radiation Oncology. Biol. Phys., 16, 1021-1024 (1989).
DeLuca et al., "Parenteral Drug-Delivery Systems," in Pharmaceutics and Pharmacy Practice (Banker et al., eds.), 238-250 (J.B. Lippincott Co., Philadelphia, PA) (1982).
Drago et al., "The Reaction of Nitrogen(II) Oxide with Various Primary and Secondary Amines," J. Am. Chem. Soc., 83, 1819-1822 (1961).
Drago, "Reactions of Nitrogen(II) Oxide," in Free Radicals in Organic Chemistry, Advances in Chemistry Series No. 36, 143-149 (American Chemical Society, Washington, DC) (1962).
Fast et al., "Nitric Oxide Production by Tumor Targets in Response to TNF: Paradoxical Correlation With Susceptibility to TNF-Mediated Cytotoxicity Without Direct Involvement in the Cytotoxic Mechanism," J. Leukocyte Biol., 52, 255-261 (1992).
Feelisch et al., "On the Mechanism of NO Release from Sydnonimines," J. Cardiovasc. Pharmacol., 14, S13-S22 (1989).
Feelisch, "The Biochemical Pathways of Nitric Oxide Formation from Nitrovasodilators: Appropriate Choice of Exogenous NO Donors and Aspects of Preparation and Handling of Aqueous NO Solutions," J. Cardiovasc. Pharmacol., 17, S25-S33 (1991).
Feldman et al., "The surprising life of nitric oxide," Chemical & Engineering News, 71, 26-38 (1993).
Filep et al., "Nitric Oxide Modulates Vascular Permeability in the Rat Coronary Circulation," Br. J. Pharmacol., 108, 323-326 (1993).
Fujitsuka et al., "Nitrosohydroxylamines," Chem. Abstracts, 82, 31108P (1975).
Furchgott, "The Role of Endothelium in the Responses of Vascular Smooth Muscle to Drugs," Ann. Rev. Pharmacol. Toxicol., 24, 175-97 (1984).
Gambassi et al., "Ischemia-Reperfusion Injury and Histamine Release in Isolated Perfused Guinea-Pig Heart: Effects of Nitric Oxide Generators," Pharmacological Research, 25, 11-12 (1992).
Garg et al., "Nitric Oxide-Generating Vasodilators Inhibit Mitogenesis and Proliferation of Balb/C3T3 Fibroblasts By A Cylic GMP-Independent Mechanism," Biochem. and Biophys. Res. Comm., 171, 474-479 (1990).
Gatenby et al., "Oxygen Distribution in Squamous Cell Carcinoma Metastases and its Relationship to Outcome of Radiation Therapy," I. J. Radiation Oncology Biol. Phys., 14, 831-838 (1988).
Gehlen et al., "Uber Reaktionen und Eigenschaften des Stickoxyds und seiner Verbindungen (II.Mitteil): Zur Kenntnis der Salze der Stickoxyd-schwefligen Saure," Berichte d. D. Chem. Gesellschaft, LXV, 1130-1140 (1932). (Reactions and properties of nitric oxide and its compounds. II. The salts of the nitric oxide compound of sulfurous acid, Chemical Abstracts, 26, 4764-65).
Gelvan et al., "Cardiac Reperfusion Damage Prevented by a Nitroxide Free Radical," Proc. Natl. Acad. Sci. USA, 88, 4680-4684 (1991).
Granger, "Role of Xanthine Oxidase and Granulocytes in Ischemia-Reperfusion Injury," Am. J. Physiol., 255, H1269-H1275 (1988).
Hall, "The Oxygen Effect and Reoxygenation," in Radiobiology for the Radiologist (4th ed.), 133-164 (J.P. Lippincott Co., Philadelphia) (1994).
Hall et al., "Extreme Hypoxia; Its Effect on the Survival of Mammalian Cells Irradiated at High and Low Dose-Rates," Br. J. Radiol., 39, 302-307 (1966).
Halliwell et al., "Oxygen Toxicity, Oxygen Radicals, Transition Metals and Disease," Biochem. J., 219, 1-14 (1984).
Halliwell et al., "Biologically Relevant Metal Ion-Dependent Hydroxyl Radical Generation," FEBS, 307, 108-112 (1992).
Halliwell et al., "Oxygen Free Radicals and Iron in Relation to Biology and Medicine: Some Problems and Concepts," Arch. Biochem. and Biophys., 246, 501-514 (1986). H!-Dopamine From Striatal Slices," Neuroreport, 3, 409-412 (1992).
Hansen et al., "N-Nitrosation of Secondary Amines by Nitric Oxide via the `Drago Complex`," in N-Nitroso Compounds: Occurrence and Biological Effects, IARC Scientific Publications No. 41, 21-29 (International Agency for Research on Cancer, Lyon, France) (1982).
Hibbs et al., "Nitric Oxide: A Cytotoxic Activated Macrophage Effector Molecule," Biochem. and Biophys. Res. Comm., 157, 87-94 (1988).
Holford et al., "Understanding the Dose-Effect Relationship: Clinical Application of Pharmacokinetic-Pharmacodynamic Models," Clinical Pharmacokinetics, 6, 429-453 (1981).
Howard-Flanders, "Effect of Nitric Oxide on the Radiosensitivity of Bacteria," Nature, 180, 1991-1192 (1957).
Hrabie et al., "New Nitric Oxide-Releasing Zwitterions Derived
Billiar Timothy R.
Keefer Larry K.
Saavedra Joseph E.
Henley III Raymond
The United States of America as represented by the Secretary of
The University of Pittsburgh
LandOfFree
Selective prevention of organ injury in sepsis and shock using s does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective prevention of organ injury in sepsis and shock using s, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective prevention of organ injury in sepsis and shock using s will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-662767